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During its 25th anniversary year, the National Alopecia Areata Foundation undertook a project to completely re-
evaluate their research program and to help focus and direct future directions of alopecia areata research to
better meet the goals of people with alopecia areata (AA) and the scientists working to discover mechanisms of
disease and better treatments for AA. This project was embodied in four research summits in 2008, 2009, 2010, and
2012, as part of the Foundation’s main strategic initiative, the Alopecia Areata Treatment Development Program to
accelerate progress toward a viable alopecia areata treatment. The first summit was an evaluation of the progress
of AA research in a global sense, with an emphasis on how to use the research programs to bring better
treatments to patients. The second summit focused on immunology and how to better understand the
autoimmune nature of AA. The third summit focused on developing a clinical research network that could
most effectively bring new treatments to patients. The fourth summit consolidated the considerable evidence of
the mechanisms of AA, and how these mechanisms could be targeted by modern therapies, many of which
were being used effectively in other autoimmune diseases. These four summits laid the foundation for the fifth
summit in the series: From Targets to Treatments: Bridging Autoimmune Research to Advance Understanding of
Alopecia Areata.
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Alopecia areata (AA) is a complex
genetic, immune-mediated disease that
targets anagen hair follicles (Alkhalifah
et al., 2010; Gilhar et al., 2012). The
disease is characterized by round or
oval patches of hair loss, which may
assume a variety of patterns: loss of all
scalp hair (alopecia totalis), loss of all
body hair (alopecia universalis), or
extensive loss on the occipital and
parietal scalp (ophiasis pattern hair
loss). Nail abnormalities may precede,
follow, or occur concurrently with hair
loss activity. About 50–80% have spora-
dic or patchy alopecia areata patchy
while alopecia areata totalis and alope-
cia areata universalis are much more
rare. The diseases associated with alo-
pecia areata in studies around the world
include vitiligo, hypo- and hyperthyr-
oidism, and atopy. Males and females of
all ages can be affected, though onset is
often found in childhood, and there is
no known racial, ethnic, or gender
preponderance. A recent study found a
cumulative lifetime incidence of 2.1%
that translates into 6.5 million people in
the United States and 145 million
worldwide who have, had, or will
develop alopecia areata at some point
in their lives (Mirzoyev et al., 2014).
Alopecia areata can have devastating
effects on an affected person’s quality
of life and people with the disease are
searching for an effective treatment or
cure. Currently there are no treatments
with Food and Drug Administration
(FDA)-approval for this indication, and
a recent Cochrane review notes that
there are no treatments that have been
shown to induce long-term benefit in
alopecia areata (Delamere et al., 2008).
They concluded, ‘‘There is a desperate
need for large well conducted studies
that evaluate long-term effects of
therapies on quality of life.’’
During its 25th anniversary year, the
National Alopecia Areata Foundation
undertook a project to completely re-
evaluate their research program and to
help focus and direct future directions of
alopecia areata research to better meet
the goals of people with AA and the
scientists working to discover mechan-
isms of disease and better treatments for
AA. This project was embodied in four
research summits in 2008, 2009, 2010,
and 2012, as part of the Foundation’s
main strategic initiative, the Alopecia
Areata Treatment Development Program
to accelerate progress toward a viable
alopecia areata treatment. The first sum-
mit was an evaluation of the progress of
AA research in a global sense, with an
emphasis on how to use the research
programs to bring better treatments to
patients. The second summit focused on
immunology and how to better under-
stand the autoimmune nature of AA.
Several projects were proposed to iden-
tify specific targets of the immune
response in AA, and to develop animal
MEETING REPORT
1Department of Dermatology, University of Colorado School of Medicine, University of Colorado Denver, Aurora, Colorado, USA
Correspondence: David A. Norris, Department of Dermatology, University of Colorado School of Medicine, 12801 East 17th Avenue, Aurora, Colorado 80045,
USA. E-mail: David.norris@ucdenver.edu
6 The Journal of Investigative Dermatology Symposium (2015), Volume 17 & 2015 The Society for Investigative Dermatology
models to study these mechanisms in
detail. A parallel objective was to iden-
tify drugs used in other autoimmune
diseases to treat AA.
The third summit was initiated in
response to the demand of new treat-
ments by AA patients, and focused on
developing a clinical research network
that could most effectively bring new
treatments to patients. This summit
launched a number of important initia-
tives to develop and fund a clinical
investigations network in AA, based on
the framework of the Alopecia Areata
Registry:
1. Develop a uniform AA clinical
research platform that stratifies extent
and duration, has a crossover com-
ponent, and an unambiguous end
point.
2. Mine the National Alopecia Areata
Registry data and publish quality-of-
life data on AA.
3. Identify biomarkers from previous AA
studies.
4. Develop a translational clinical
research platform with biomarkers
(Skin, serum, whole blood, RNA,
and DNA).
5. Develop a plan to approach multiple
pharmaceutical companies to use
drugs in development of already
approved for other diseases in AA.
6. Develop a strategy to assist indivi-
dual investigators in submitting
grants to NIAMS to support clinical
pilot and feasibility studies.
The fourth summit consolidated the
considerable evidence of the mechan-
isms of AA, and how these mechanisms
could be targeted by modern therapies,
many of which were being used effec-
tively in other autoimmune diseases.
We learned that:
1. Both innate and acquired immunity
are involved in AA.
2. Both genetic and functional immu-
nologic studies have identified com-
plex immunologic networks in both
human- and animal-model AA.
NKG2D ligands, interleukin (IL)-15,
CTLA-4, and Jak signaling have
emerged as attractive targets for treat-
ment of AA using modern biologic
and pharmacologic approaches.
3. Modulation of immune privilege
continues to be an intriguing target
to modulate AA induction and
progression.
4. The specificity of the immune
response in AA is still unknown.
Pigmented anagen hair follicles
appear to be the target. Whether
antigen-specific activated T cells or
antibodies are required for AA is not
yet known.
The fourth summit focused on identi-
fying attractive targets for treatment of
AA using modern biologic and pharma-
cologic approaches and developing a
robust clinical research platform to facil-
itate the testing of a number of new
drugs being effectively used in other
autoimmune diseases. The summit pro-
vided a number of recommendations for
future research to achieve the
goal of finding safe, effective affordable
FDA-approved treatment for alopecia
areata.
Genetics
1. Execute combined association and
linkage studies using 250 multiplex
families from the Alopecia Areata
Registry, Biobank and Clinical Trials
Network (formerly known as
National Alopecia Areata Registry).
2. Utilize functional genomics with
deep sequencing.
3. Develop a network plot of pathways
activated in alopecia areata.
4. Determine the percentage of people
with alopecia areata compared with
the normal population with specified
genes.
5. Analyze shared variants among
related diseases, including celiac dis-
ease, rheumatoid arthritis, and type 1
diabetes (five loci are shared
between type 1 diabetes and alope-
cia areata).
6. Increase the number of alopecia
areata samples in the BioBank to
10,000.
7. Determine if there is a genetic basis
for disease subsets, i.e., alopecia
areata, alopecia totalis, and alopecia
universalis.
8. Analyze National Alopecia Areata
Registry, Biobank and Clinical Trials
Network samples to determine
whether alopecia areata is a compo-
site of several different disease
processes and the possibility that
there are actually many treatment
modalities.
Immunology
1. Study how to restore immune
privilege.
2. Analyze the potential of targeting the
IL-15 pathway.
3. Identify the protolerance TCR signal;
then target it pharmacologically.
4. Develop TCR sequencing.
5. Complete biomarker studies.
Animal models
1. Identify and develop mouse and
humanized mouse models.
2. Validate these models.
3. Determine which model will be the
best to replicate alopecia areata.
Clinical
1. Finalize and validate the Alopecia
Areata Uniform Protocol for clinical
trials.
2. Publish quality-of-life studies.
3. Publish incidence and prevalence
studies.
4. Initiate additional burden of disease
studies.
5. Use pharmacogenomics to predict
which patient populations will
respond and which will get side
effects.
6. Determine the attractive pathways
for targeted therapy.
The recent advancements and discov-
eries in AA research through the efforts
of NAAF and four highly successful
research summits laid the groundwork
for the fifth summit in the series: From
Targets to Treatments: Bridging Autoim-
mune Research to Advance Understand-
ing of Alopecia Areata. This meeting,
held in December 2014, represented the
successful collaborative efforts of the AA
research community with research
advances into the cause and mechan-
isms of AA and early-stage clinical
trials of drugs targeting autoimmune
pathways showing promising hair
regrowth.
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